RESUMEN
Almost 43 million people in India are harbouring hepatitis B virus (HBV) in their blood. Chronic HBV infection may be with or without sign/symptom of liver disease. Children are more prone to suffer from chronic HBV infection compared to adults and adolescents. Treatment aims at prevention of its sequelae namely cirrhosis and subsequent hepatocellular carcinoma. At the moment two major groups of agents are available for treatment. These are (a) immunomodulators and (b) antivirals. Present research aims at identification of a suitable agent to act on HBV covalently closed circular DNA persisting in hepatic cells for complete eradication of HBV.
Asunto(s)
Antivirales/uso terapéutico , Hepatitis B Crónica/tratamiento farmacológico , Humanos , India/epidemiología , Interferón-alfa/uso terapéutico , Lamivudine/uso terapéutico , Selección de Paciente , Timosina/uso terapéuticoAsunto(s)
Anciano , Aneurisma/diagnóstico , Aneurisma Roto/diagnóstico , Hemobilia/etiología , Arteria Hepática , Humanos , MasculinoRESUMEN
The binding of Ricinus communis agglutinin and Abrus agglutinin to 4-methylumbelliferyl β-D-galactopyranoside was studied by equilibrium dialysis, fluorescence quenching and fluorescence polarization. The number of binding sites and the association constant value obtained by fluorescence polarization for both Ricinus communis agglutinin and Abrus agglutinin are in close agreement with those obtained by the other methods. This indicates the potential of ligand-fluorescence polarization measurements in the investigation of lectin-sugar interactions.